Exenatide antidiabetic drugs

AC 2993 - Byetta - AC 2993 LAR - exendin 4 - Ex4 peptide - exendin-4 - bydureon - exenatide

Diabetes type 2

All type of patients:  42 trials  - Davis - Barnett - Nauck - Heine - DeFronzo 10µg/d - Zinman 20µg/j - Buse 10µg/d - Kendall 20µg/d - Kadowaki (trial 8683) - Kim - Moretto (DOUBLONS avec druker) - DURATION-3 (Diamant) - DURATION-2 (Bergenstal) (vs sitagliptin) - DURATION-2 (Bergenstal) (vs pioglitazone) - Buse - H8O-MC-GWDE - NCT00085969 - DeFronzo - Fineman - Poon - Zinman 20µg/j A MODIFIER - Trial 8078 - Gao - Exenatide Trial 10749 - H8O-MC-GWBJ, 9698, 20µg/d - phase 2 exenatide once monthly - DeFronzo 20µg/d - Buse 20µg/d - Kendall 10µg/d - Apovian - Bergenstal (once daily) - Bergenstal (twice daily) - Bunck - DeFronzo (EXE vs ROSI) - Drucker - HEELA (Davies) - LEAD 6 (Buse) exe vs lira - Gill - H8O-MC-GWBJ, 9698, 10µg/d - Liutkus - Derosa - NCT00360334

exenatide vs glargine

No demonstrated result

exenatide vs placebo

No demonstrated result

exenatide 10µg twice daily vs liraglutide 1.8mg

No demonstrated result

exenatide 10µg/d vs placebo

No demonstrated result

exenatide 10µg/d vs placebo (add on MET)

No demonstrated result

exenatide 10µg/d vs placebo (add on SU)

No demonstrated result

A CHANGER by 436% (harmful effect)

vomiting by 294% (harmful effect)

exenatide 10µg/d vs placebo (add on SU+/-MET/TZD)

No demonstrated result

exenatide 10µg/d vs placebo (add on SU+MET)

No demonstrated result

A CHANGER by 90% (harmful effect)

vomiting by 230% (harmful effect)

exenatide 10µg/d vs placebo add on MET+/-TZD

No demonstrated result

exenatide 20µg vs glibenclamide

No demonstrated result

exenatide 20µg/d vs BIAsp 30 daily

No demonstrated result

exenatide 20µg/d vs BIAsp 30 twice daily

No demonstrated result

exenatide 20µg/d vs insulin (add on SU+MET)

No demonstrated result

A CHANGER by 563% (harmful effect)

vomiting by 364% (harmful effect)

diarrhoea by 184% (harmful effect)

exenatide 20µg/d vs insulin (add on SU/MET)

No demonstrated result

A CHANGER by 838% (harmful effect)

vomiting by 220% (harmful effect)

exenatide 20µg/d vs insulin BIAsp twice daily add on SU+MET

No demonstrated result

A CHANGER by 8134% (harmful effect)

vomiting by 366% (harmful effect)

diarrhoea by 371% (harmful effect)

exenatide 20µg/d vs insulin glargine (add on MET)

No demonstrated result

exenatide 20µg/d vs placebo

No demonstrated result

exenatide 20µg/d vs placebo (add on insulin)

No demonstrated result

A CHANGER by 399% (harmful effect)

vomiting by 345% (harmful effect)

diarrhoea by 123% (harmful effect)

exenatide 20µg/d vs placebo (add on MET)

No demonstrated result

exenatide 20µg/d vs placebo (add on MET+/-SU)

No demonstrated result

all hypoglycemia by 292% (harmful effect)

treatment-emergent adverse events (TEAEs) by 58% (harmful effect)

A CHANGER by 2825% (harmful effect)

vomiting by 7336% (harmful effect)

exenatide 20µg/d vs placebo (add on SU)

No demonstrated result

exenatide 20µg/d vs placebo (add on SU+MET)

No demonstrated result

all hypoglycemia by 277% (harmful effect)

A CHANGER by 135% (harmful effect)

vomiting by 207% (harmful effect)

diarrhoea by 169% (harmful effect)

exenatide 20µg/d vs placebo (add on TZD+/-MET)

No demonstrated result

A CHANGER by 161% (harmful effect)

vomiting by 1381% (harmful effect)

exenatide 20µg/d vs rosiglitazone add on MET

No demonstrated result

exenatide 20µg/d vs sitagliptin (add on MET)

No demonstrated result

exenatide 20µg/d vs weekly exenatide

No demonstrated result

exenatide before lunch and dinner vs exenatide before breakfast and dinner

No demonstrated result

exenatide once monthly vs weekly exenatide

No demonstrated result

exenatide other doses vs glargine

No demonstrated result

exenatide other doses vs insulin glargine (add on MET/SU)

No demonstrated result

exenatide other doses vs placebo

No demonstrated result

exenatide other doses vs placebo (add on MER+/-SU)

No demonstrated result

exenatide weekly vs insulin glargine

No demonstrated result

A CHANGER by 857% (harmful effect)

diarrhoea by 139% (harmful effect)

exenatide weekly vs liraglutide

No demonstrated result

exenatide weekly vs pioglitazone

No demonstrated result

exenatide weekly vs placebo (add on MET)

No demonstrated result

exenatide weekly vs sitagliptin

No demonstrated result

See more clinical conditions

Patients inadequately controlled on MET+SU therapy :  4 trials  - Nauck - Heine - Kendall 20µg/d - Kendall 10µg/d

exenatide 10µg/d vs placebo (add on SU+MET)

No demonstrated result

A CHANGER by 90% (harmful effect)

vomiting by 230% (harmful effect)

exenatide 20µg/d vs insulin (add on SU+MET)

No demonstrated result

A CHANGER by 563% (harmful effect)

vomiting by 364% (harmful effect)

diarrhoea by 184% (harmful effect)

exenatide 20µg/d vs insulin BIAsp twice daily add on SU+MET

No demonstrated result

A CHANGER by 8134% (harmful effect)

vomiting by 366% (harmful effect)

diarrhoea by 371% (harmful effect)

exenatide 20µg/d vs placebo (add on SU+MET)

No demonstrated result

all hypoglycemia by 277% (harmful effect)

A CHANGER by 135% (harmful effect)

vomiting by 207% (harmful effect)

diarrhoea by 169% (harmful effect)

Patients inadequately controlled on metformin:  4 trials  - DeFronzo 10µg/d - Kim - Gao - DeFronzo 20µg/d

exenatide 10µg/d vs placebo (add on MET)

No demonstrated result

exenatide 20µg/d vs placebo (add on MET)

No demonstrated result

exenatide 20µg/d vs placebo (add on MET+/-SU)

No demonstrated result

all hypoglycemia by 292% (harmful effect)

treatment-emergent adverse events (TEAEs) by 58% (harmful effect)

A CHANGER by 2825% (harmful effect)

vomiting by 7336% (harmful effect)

exenatide weekly vs placebo (add on MET)

No demonstrated result

Patients inadequately controlled on monotherapy :  9 trials  - DeFronzo 10µg/d - Buse 10µg/d - Kim - Fineman - Trial 8078 - Gao - Exenatide Trial 10749 - DeFronzo 20µg/d - Buse 20µg/d

exenatide 10µg/d vs placebo (add on MET)

No demonstrated result

exenatide 10µg/d vs placebo (add on SU)

No demonstrated result

A CHANGER by 436% (harmful effect)

vomiting by 294% (harmful effect)

exenatide 20µg/d vs placebo (add on MET)

No demonstrated result

exenatide 20µg/d vs placebo (add on MET+/-SU)

No demonstrated result

all hypoglycemia by 292% (harmful effect)

treatment-emergent adverse events (TEAEs) by 58% (harmful effect)

A CHANGER by 2825% (harmful effect)

vomiting by 7336% (harmful effect)

exenatide 20µg/d vs placebo (add on SU)

No demonstrated result

exenatide before lunch and dinner vs exenatide before breakfast and dinner

No demonstrated result

exenatide other doses vs insulin glargine (add on MET/SU)

No demonstrated result

exenatide other doses vs placebo (add on MER+/-SU)

No demonstrated result

exenatide weekly vs placebo (add on MET)

No demonstrated result

Patients inadequately controlled with insulin:  7 trials  - Davis - Barnett - Nauck - Heine - DURATION-3 (Diamant) - Buse - Trial 8078

exenatide 20µg/d vs insulin (add on SU+MET)

No demonstrated result

A CHANGER by 563% (harmful effect)

vomiting by 364% (harmful effect)

diarrhoea by 184% (harmful effect)

exenatide 20µg/d vs insulin (add on SU/MET)

No demonstrated result

A CHANGER by 838% (harmful effect)

vomiting by 220% (harmful effect)

exenatide 20µg/d vs insulin BIAsp twice daily add on SU+MET

No demonstrated result

A CHANGER by 8134% (harmful effect)

vomiting by 366% (harmful effect)

diarrhoea by 371% (harmful effect)

exenatide 20µg/d vs placebo (add on insulin)

No demonstrated result

A CHANGER by 399% (harmful effect)

vomiting by 345% (harmful effect)

diarrhoea by 123% (harmful effect)

exenatide other doses vs insulin glargine (add on MET/SU)

No demonstrated result

exenatide weekly vs insulin glargine

No demonstrated result

A CHANGER by 857% (harmful effect)

diarrhoea by 139% (harmful effect)

Patients with insufficient glycaemic control with bitherapy:  11 trials  - Davis - Nauck - Heine - Zinman 20µg/j - Kendall 20µg/d - Kadowaki (trial 8683) - Fineman - Zinman 20µg/j A MODIFIER - Gao - phase 2 exenatide once monthly - Kendall 10µg/d

exenatide 10µg/d vs placebo (add on SU+/-MET/TZD)

No demonstrated result

exenatide 10µg/d vs placebo (add on SU+MET)

No demonstrated result

A CHANGER by 90% (harmful effect)

vomiting by 230% (harmful effect)

exenatide 20µg/d vs insulin (add on SU+MET)

No demonstrated result

A CHANGER by 563% (harmful effect)

vomiting by 364% (harmful effect)

diarrhoea by 184% (harmful effect)

exenatide 20µg/d vs insulin (add on SU/MET)

No demonstrated result

exenatide 20µg/d vs insulin BIAsp twice daily add on SU+MET

No demonstrated result

A CHANGER by 8134% (harmful effect)

vomiting by 366% (harmful effect)

diarrhoea by 371% (harmful effect)

exenatide 20µg/d vs placebo (add on MET+/-SU)

No demonstrated result

all hypoglycemia by 292% (harmful effect)

treatment-emergent adverse events (TEAEs) by 58% (harmful effect)

A CHANGER by 2825% (harmful effect)

vomiting by 7336% (harmful effect)

exenatide 20µg/d vs placebo (add on SU+MET)

No demonstrated result

all hypoglycemia by 277% (harmful effect)

A CHANGER by 135% (harmful effect)

vomiting by 207% (harmful effect)

diarrhoea by 169% (harmful effect)

exenatide 20µg/d vs placebo (add on TZD+/-MET)

No demonstrated result

A CHANGER by 161% (harmful effect)

vomiting by 1381% (harmful effect)

exenatide once monthly vs weekly exenatide

No demonstrated result

exenatide other doses vs placebo (add on MER+/-SU)

No demonstrated result